All News
View More
Music shows promise for sleep while many wellness apps lack strong proof

Recent research compares sleep aids in apps—sonic sleep sounds, white noise and pink noise—and warns weak evidence may waste money and delay proven insomnia care.

Heart failure patients who receive text messages less likely to return to hospital

Rural hospital study found text messaging intervention significantly improved medication adherence for heart failure patients, demonstrating that simple technology can reduce readmissions.

Reproductive factors strongly influence ovarian cancer risk in postmenopausal women

A large Korean, population-based study of more than 2 million women suggests that patterns across a woman’s reproductive life may influence ovarian cancer risk, with some factors increasing risk and others appearing protective.

ENA respiratory launches phase 2 community study of INNA-051 nasal spray
Understanding the facial effects of GLP-1s with plastic surgeon, Konstantin Vasyukevich, M.D.

Patients using GLP-1 medications may notice facial changes due to fat loss. Vasyukevich stresses education and options for maintaining a youthful appearance.

ACHP announces new funding to elevate patient voices in diabetes research

The award will involve patients with chronic disease and their families to inform clinical research, with an initial focus on diabetes.

Melanoma diagnoses projected to rise in 2026

Estimates show melanoma diagnoses continuing to climb in the United States, even as newer therapies continue to reduce deaths from advanced disease.

Study of antibody-Keytruda combination seeds hope for overcoming immune checkpoint inhibitor resistance, use of biomarkers
Myqorzo is now available for rare heart condition at a $108,400 annual price

Myqorzo was approved in December to treat adults with obstructive hypertrophic cardiomyopathy. It is available through a REMS program and has a boxed warning about the risk of heart failure.

Advertisement
Advertisement

Official Media Partners